CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, whose expression is upregulated in squamous cell carcinomas of the lung, esophagus, uterus and oral cavity. CD109 negatively regulates transforming growth factor (TGF)-b signaling in keratinocytes by directly modulating receptor activity. In this study, we further characterized CD109 regulation of TGF-b signaling and cell proliferation. We found that CD109 is produced as a 205 kDa glycoprotein, which is then processed in the Golgi apparatus into 180 kDa and 25 kDa proteins by furin (furinase). 180 kDa CD109 associated with GPI-anchored 25 kDa CD109 on the cell surface and was also secreted into the culture medium. To investigate whether furinase cleavage of CD109 is necessary for its biological activity, we mutated arginine 1273 in the CD109 furinase cleavage motif (amino acid 1270-RRRR-1273) to serine (R1273S). Interestingly, CD109 R1273S neither significantly impaired TGF-b signaling nor affected TGF-b-mediated suppression of cell growth, although it was expressed on the cell surface as a 205 kDa protein. Consistent with this finding, the 180 kDa and 25 kDa CD109 complex, but not CD109 R1273S, associated with the type I TGF-b receptor. These findings indicate that processing of CD109 into 180 kDa and 25 kDa proteins by furin, followed by complex formation with the type I TGF-b receptor is required for the regulation of TGF-b signaling in cancer cells and keratinocytes.
Introduction
A variety of growth factors are involved in the signaling pathways that regulate cancer progression or suppression. Transforming growth factor-b (TGF-b) is one of the most important growth factors for modulating the nature of cancer cells (Derynck et al., 2001) . TGF-b represents a large superfamily of dimeric growth factors that induce a wide range of biological responses, including cell proliferation, differentiation, migration and apoptosis. In mammals, the TGF-b superfamily can be categorized into three subfamilies: bone morphogenetic protein, activin/inhibin/nodal and TGF-b. The TGF-b subfamily is composed of three isoforms; TGFb1, -b2 and -b3 (Dennler et al., 2002) . The TGF-b signaling pathway is transduced by two single transmembrane domain Ser/Thr kinase receptors; Type I (TbRI) and type II (TbRII) (Shi and Massague´, 2003) . Ligand-mediated assembly of TbRI and TbRII initiates an intracellular phosphorylation cascade in which the activated TbRII transphosphorylates the GS domain of TbRI. Subsequently, TbRI phosphorylates receptorregulated Smads (R-Smads; for example, Smad2/3), which can then bind a coSmad (for example, Smad4). R-Smad/coSmad complexes translocate and accumulate in the nucleus where they act as transcription factors of target genes (Massague´et al., 2005) . TGF-b/Smad signaling upregulates several inhibitors of cyclin-dependent kinases, such as p15 Ink4B , p21 Cip1 and p27
Kip1
, thereby mediating G1 cell-cycle arrest and an antiproliferative effect (Moustakas et al., 2002; Pardali and Moustakas, 2007) . Thus, disruption of the TGF-b signaling pathway could result in enhanced cell proliferation. Indeed, mutations in TGF-b receptors or in downstream signaling molecules have been associated with the development of colorectal and pancreatic cancers (Xu et al., 2000; Jakowlew, 2006) . CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein and is a member of the a2-macroglobulin (a2 M) -C3, C4 and C5 family (Sutherland et al., 1991; Haregewoin et al., 1994; Lin et al., 2002) . CD109 was first identified as a cell-surface antigen, detected in the lymphoid/myeloid cell line KG1a (Sutherland et al., 1991) . CD109 is expressed on a subset of fetal and adult CD34 þ bone marrow mononuclear cells, mesenchymal stem cell subsets, phytohemagglutinin-activated T lymphoblasts, thrombinactivated platelets, leukemic megakaryoblasts, endothelial cells and some human tumor cell lines (Kelton et al., 1990; Murray et al., 1999; Giesert et al., 2003) . Tam et al. (2003) and Finnson et al. (2006) reported that CD109 was a component of the TGF-b receptor system and that it decreased TGF-b1-induced phosphorylation of R-Smad in human keratinocytes. We recently found that CD109 was upregulated in oral squamous cell carcinoma (SCC), which resulted in a reduction of the TGF-b1-mediated anti-proliferative effect in oral SCC cells . In addition, the expression levels of the CD109 transcript were significantly increased in SCCs of esophagus, lung and uterus (Hashimoto et al., 2004; Zhang et al., 2005) . Immunohistochemical analyses using an anti-CD109 antibody revealed that high levels of CD109 were frequently detected in lung and oral cavity SCCs compared with other types of carcinoma Hagiwara et al., 2008) . On the other hand, CD109 immunoreactivity in normal tissues was detected in a restricted number of cell types, such as myoepithelial cells of the breast, salivary, lacrimal and bronchial secretary glands and basal cells of the prostate and bronchial epithelia Hagiwara et al., 2008; Hasegawa et al., 2007 Hasegawa et al., , 2008 . These findings suggested that CD109 may have a critical role in cancer development, especially in SCCs.
In this study, we further analyzed CD109 regulation of TGF-b signaling. The 205 kDa glycosylated form of CD109 was processed in the Golgi apparatus into 180 kDa and 25 kDa forms by furinase. This cleavage was required for association of CD109 with TbRI, thereby negatively regulating TGF-b signaling. Our findings provide new insight into the mechanism of TGF-b signaling regulation by CD109 in cancer cells. Figure 1a shows the structure of the FLAG-tagged CD109 protein. It contains an amino-terminal signal sequence, a thioester signature motif (amino acids [aa.] 918-924), a potential furinase cleavage site (aa. 1270-1273) and a GPI-anchor cleavage-addition site (aa. 1420-1445) (amino acid numbering does not include the FLAG sequence). To characterize the CD109 protein, we generated three anti-CD109 antibodies; anti-CD109-2 and anti-CD109-4 are rabbit polyclonal antibodies and 11H3 is a mouse monoclonal antibody ( Figure 1a , also see Materials and methods). Anti-CD109-2 and 11H3 were generated against the same peptide (aa. 1383-1399).
Results

Generation of CD109 antibodies that recognize different epitopes
Western blot analyses using the lysates of HEK293 cells transfected with the FLAG-tagged CD109 cDNA revealed that anti-FLAG and anti-CD109-4 antibodies recognized a major 180 kDa and a minor 190 kDa band, whereas the anti-CD109-2 antibody recognized 190 kDa and 25 kDa bands (Figure 1b) . The 11H3 monoclonal antibody also detected both 190 kDa and 25 kDa bands (Figure 1b) . Anti-FLAG and anti-CD109-2 antibodies stained the plasma membrane and the cytoplasm of the HEK293-CD109 transfectants (Figure 1c) . The anti-CD109-4 antibody was not available for immunocytochemistry. To confirm that these bands represent the CD109 protein, CD109 siRNA was transfected into HEK293 and HEK293-CD109 cells and also into A431 and SK-MES-1 human squamous cell carcinoma cell lines. Their lysates were then subjected to western blot analysis. The intensities of the 190 kDa, 180 kDa and 25 kDa bands were markedly reduced in CD109 siRNAtreated cells (Figure 1d ), indicating that these bands represent the CD109 proteins.
CD109 is cleaved by furinase
As CD109 has a potential furinase cleavage motif (Figure 1a) , we investigated whether CD109 is processed by furinase. Furin (furinase) is a major processing enzyme in the secretary pathway, and is mainly localized in the trans-Golgi network (Ouweland et al., 1990; Steiner, 1998) . When 293-CD109 cells were treated with a furinase inhibitor (FI-I), a novel band of 205 kDa appeared on western blots using anti-FLAG, anti-CD109-4 and anti-CD109-2 antibodies (Figure 2a ). Treatment with higher concentrations of FI-I increased the intensity of the 205 kDa band. In contrast, the intensities of the 180 kDa and 25 kDa bands decreased (Figure 2a ), suggesting that 205 kDa CD109 is cleaved into 180 and 25 kDa CD109 by furinase.
The minimal sequence recognized by furinase is Arg-X-(Lys/Arg)-Arg and cleavage occurs at the C-terminal peptide bond of Arg (Molloy et al., 1992; Rouille´et al., 1995) . To confirm that CD109 is cleaved at this motif (aa. 1270-1273: -ArgArgArgArg-), the arginine at 1273 was replaced with serine ( Figure 2b ) and a HEK293 transfectant expressing the mutant CD109 cDNA was established (designated R1273S cells). As shown in Figure 2c , the anti-FLAG, anti CD109-2 and anti-CD109-4 antibodies all detected a major 205 kDa band and a minor 190 kDa band. The levels of 180 kDa and 25 kDa CD109 were drastically decreased in the R1273S cells. This finding further suggested that 180 and 25 kDa bands represent products processed from the 205 kDa precursor by furinase.
180 and 25 kDa forms of CD109 are localized on the plasma membrane To elucidate which CD109 form is present on the cell surface, 293-CD109 cell surface proteins were biotinylated. 293-CD109 cell lysates were then immunoprecipitated with anti-FLAG antibody and then reacted with anti-FLAG, anti-CD109-2, anti-CD109-4 or streptavidin. As shown in Figure 3a , streptavidin detected 180 kDa and 25 kDa CD109 but not 190 kDa CD109, indicating the former two CD109 proteins are present on the cell surface. This result also indicates that 190 kDa CD109 is localized in the cytoplasm. The lysate of R1273S cells was also immunoprecipitated with anti-FLAG antibody, followed by reaction with streptavidin. This analysis showed that 205 kDa CD109 was present on the cell surface (Figure 3b ). CD109 is a GPI-anchored glycoprotein of 1445 amino acids (aa). N-terminal signal sequence, thioester signature motif, furinase cleavage motif and C-terminal GPI-cleavage site are indicated. FLAG sequence was inserted after the N-terminal signal sequence. The peptides against which anti-CD109 polyclonal antibodies (pAb) were generated are shown (designated CD109-4 and CD109-2). 11H3 is a mouse monoclonal antibody which was generated against the same peptide as anti-CD109-2 pAb. (b) Detection of CD109 protein. FLAG-tagged CD109 cDNA was transfected into HEK293 cells and a stable transfectant was established. Total cell lysates were prepared from VC (vector control) and CD109-overexpressing cells, and subjected to western blot analysis with the indicated antibodies. A 190 kDa band (white arrowhead) was detected by all antibodies. 180 kDa (black arrowhead) and 25 kDa (gray arrowhead) bands were detected by anti-FLAG/CD109-4 and anti-CD109-2/11H3 antibodies, respectively. (c) Immunofluorescence analysis of CD109 in transfected cells. 293-VC and -CD109 transfectants were fixed and stained with anti-FLAG and anti-CD109-2 antibodies. CD109 was detected in the plasma membrane and in the cytoplasm. ICS: immunocytochemical staining. Yellow bar: 10 mm. (d) Knockdown of CD109 expression using siRNA. 293-CD109, HEK293, A431 (skin squamous cell carcinoma) and SK-MES-1 (lung squamous cell carcinoma) cells were treated with 50 pM CD109 siRNA and analyzed by western blotting with the indicated antibodies. Exogenous CD109 in 293-CD109 cells and endogenous CD109 in HEK293, A431 and SK-MES-1 cells were detected. Expression of 190 kDa, 180 kDa and 25 kDa CD109 was markedly decreased.
Role of furin-processed CD109 in TGF-b signaling S Hagiwara et al GPI-anchored proteins are thought to be recruited to lipid rafts on the plasma membrane. Thus, cells were treated with the non-ionic detergent, n-octyl-b-D-glucopyranoside (nOG), which can dissolve lipid rafts (Garcia et al., 1993) . Treatment with increasing concentrations of nOG (0-2%) resulted in the immunoprecipitation of increasing amounts of 25 kDa CD109 with the anti-CD109-2 antibody ( Figure 3c ). In contrast, although the amount of 180 kDa CD109 detected with anti-FLAG and anti-CD109-4 antibodies increased after adding 0.5% nOG, it did not appear to increase further with higher concentrations (1-2%) of nOG. In addition, the amount of 190 kDa CD109 did not significantly change with nOG treatment (Figure 3c ). These findings suggest that 25 kDa and 180 kDa CD109 is present on lipid rafts of the plasma membrane and that 25 kDa CD109 is more enriched in that fraction than 180 kDa CD109. Moreover, we found that 205 kDa R1273S mutant CD109 was enriched in the lipid raft fraction (Supplementary Figure S1 ).
CD109 is a glycoprotein
Based on its amino acid sequence, CD109 has 17 potential N-linked glycosylation sites. Tunicamycin completely inhibits mannose attachment on asparagine and is used for the detection of core proteins without Nlinked glycosylation (Struck and Lennarz, 1977; Waechter and Harford, 1977; Guarnaccia et al., 1983; Arnold et al., 2006) . When 293-CD109 and R1273S cells were treated with 5 mg/ml tunicamycin for 24 h, a 155 kDa Role of furin-processed CD109 in TGF-b signaling S Hagiwara et al band was commonly detected using the anti-FLAG, anti-CD109-2 and anti-CD109-4 antibodies ( Figure 4a ). In addition, a 130 kDa band was detected with anti-FLAG and anti-CD109-4 antibodies in the lysates from tunicamycin-treated 293-CD109 cells but not from tunicamycin-treated R1273S cells. A 25 kDa CD190 band was also detected in tunicamycin-treated 293-CD109 cells (Figure 4a ). We conclude from these findings that the 155 kDa protein represents a core polypeptide of CD109, without N-linked glycosylation, which is cleaved into 130 kDa and 25 kDa proteins by furinase in the Golgi apparatus of tunicamycin-treated cells. We suggest that the 155 kDa core polypeptide is processed in the endoplasmic reticulum and Golgi into the 190 kDa glycoprotein by the addition of high mannose oligosaccharides. 190 kDa CD109 is further processed into the mature glycosylated form of 205 kDa CD109, which is cleaved in the trans-Golgi network into 180 kDa and 25 kDa CD109 by furinase ( Figure 4c ). Finally, 180 kDa and 25 kDa CD109 are expressed on the cell surface and enriched on lipid rafts. A proposed model is illustrated in Figure 4c .
Secretion of 180 kDa CD109 into the culture medium
We next investigated whether CD109 is secreted into the culture medium. As shown in Figure 4b , 180 kDa CD109 was detected in the culture medium at a high level. Although 25 kDa CD109 and mutant 205 kDa CD109 were also detected in the medium, the ratios of 25 kDa and 205 kDa CD109 in the medium to those in the cell lysate were much lower than that of 180 kDa CD109. Thus, 180 kDa CD109 appears to be secreted into the medium as a furinase-cleaved product ( Figure 4c ). This finding also suggested that a small amount of 25 kDa and 205 kDa CD109 may be secreted by cleavage at the GPI-anchored site.
CD109 impairs TGF-b/Smad signaling and accelerates cell proliferation Earlier, we showed that CD109 impaired TGF-b1-mediated suppression of cell growth using an SAS oral squamous cell carcinoma cell line . To confirm this result, we first compared the levels of Smad2 phosphorylation between 293-VC, 293-CD109 and R1273S transfectants treated with 50 pM TGF-b1 for 1 h. As shown in Figure 5a , the level of Smad2 phosphorylation in 293-CD109 cells was significantly lower than that in 293-WT (wild-type), 293-VC and R1273S cells. A cell proliferation assay revealed that 293-CD109 cells grew significantly faster than 293-VC and R1273S cells in the absence of TGF-b1. In addition, stimulation with TGF-b1 caused a significant growth suppression of 293-VC and R1273S cells, but not of 293-CD109 cells (Figure 5b ), indicating that the processing of CD109 by furinase is necessary for its ability to impair the anti-proliferative effect of TGF-b1. The time course of TGF-b/Smad signaling was further investigated for 48 h after TGF-b1 stimulation. As shown in Figure 5c , Smad2 phosphorylation and induction of p21, which is downstream of Smad signaling, were remarkably attenuated in 293-CD109 cells compared with that in 293-VC and R1273S cells. p21 is known as an inhibitor of cyclin-dependent kinase-2, and induces a suppressive effect on the cell cycle, which is consistent with the results of the cell proliferation assay shown in Figure 5b . In addition, TGF-b1 induced upregulation of endogenous CD109 expression in 293-VC cells (Figure 5c ).
We next investigated whether treatment with FI-I affects TGF-b/Smad signaling in 293-CD109 cells. The levels of Smad2 phosphorylation induced by TGF-b1 did not significantly change between FI-I-untreated and treated 293-CD109 cells (Supplementary Figure S2a) . This was probably because FI-I treatment did not completely inhibit the cleavage of CD109 (approximately 30% of CD109 was still processed into 180 kDa CD109 in FI-I-treated 293-CD109 cells). On the other hand, inhibition of endogenous CD109 processing in HEK293 cells moderately increased the level of Smad2 phosphorylation (Supplementary Figure S2b) . CD109 modulates receptor activity by direct interaction with TbRI, independently of ligand binding (Finnson et al., 2006) . We found association of 180 kDa and 25 kDa CD109 complex with TbRI by immunoprecipitation experiments, whereas the association of TbRII with CD109 appears to be very weak or non-existent. Interestingly, CD109 R1273S was not clearly associated with TbRI, indicating that the processing of CD109 into 180 kDa and 25 kDa forms is a prerequisite for association with TbRI (Figure 5d ).
Overexpression of soluble 180 kDa CD109, but not C-terminal 25 kDa CD109 affects TGF-b signaling To investigate whether 25 kDa CD109, which is GPIanchored to lipid rafts, has an important role in TGF-b signaling, Myc-tagged C-terminal 25 kDa CD109 (designated cCD109) was constructed and cloned into pSecTag2-B (Figure 6a ). cCD109 or empty vector (pSecVC) was transiently transfected into 293 cells, and after 24 h incubation, 293-cCD109 and pSecVC transfectants were subjected to western blot analysis. As shown in Figure 6b , cCD109 was detected as a 30 kDa protein using both anti-Myc and anti-CD109-2 antibodies. Cell surface expression of cCD109 was detected by immunocytochemical analysis (Figure 6c ). These transfectants were stimulated with 50 pM TGF-b1 for 24 h and the levels of Smad2 phosphorylation were compared by western blot analysis (Figure 6d ). Smad2 phosphorylation was observed in a similar time-dependent manner in both transfectants, although expression of exogenous cCD109 gradually decreased. This finding indicates that overexpression of 25 kDa CD109 alone does not impair TGF-b/Smad signaling.
We next generated the expression plasmid carrying a FLAG-tagged truncated CD109 (aa. 1-1273) (Figure 7a ), which was transfected into HEK293 cells. As expected, this plasmid produced soluble 180 kDa CD109 proteins (designated sCD109) in the culture medium (Figure 7b) . Interestingly, expression of Role of furin-processed CD109 in TGF-b signaling S Hagiwara et al sCD109 in HEK293 cells decreased TGF-b1-mediated Smad2 phosphorylation as observed for expression of wild-type CD109. Coexpression of cCD109 and sCD109 also decreased Smad2 phosphorylation at a similar level to that in HEK293 cells transfected with sCD109 alone (Figure 7b ). Culture media from 293-VC, -CD109 and -R1273S cells, which had been incubated for 2 days, were concentrated and subjected to western blot analysis with the indicated antibodies. 180 kDa CD109 was detected at high levels in the culture medium from 293-CD109 cells by the anti-FLAG and anti-CD109-4 antibodies. 25 kDa CD109, but not 190 kDa CD109 was also detected in the medium by the anti-CD109-2 antibody, although at a low level. In addition, 205 kDa CD109 R1273S was detected at a low level in the culture medium from R1273S cells by the three antibodies. (c) A proposed model of CD109 protein processing. CD109 is synthesized as a 155 kDa core protein in the ER and linked to GPI. The core protein is glycosylated (high mannose type, B190 kDa) in the ER and transferred to the Golgi complex. 190 kDa CD109 is further glycosylated (maturation, B205 kDa) by several glycosyltransferases and then processed in the trans-Golgi network into 180 kDa and 25 kDa CD109 by furinase cleavage. Then, the complex of 180 kDa and 25 kDa CD109 is expressed on the cell surface and is enriched on lipid rafts. 180 kDa CD109 is also secreted into the culture medium.
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P-Smad2
Smad2/3 TGF-1 (50 pM) 1h The lysates from 293-CD109 or 293-R1273S cells were immunoprecipitated with normal mouse IgG (Cont.), anti-FLAG or 11H3 monoclonal antibodies, followed by western blot analysis with the indicated antibodies. CD109 but not CD109 R1273S was associated with TbRI.
Role of furin-processed CD109 in TGF-b signaling S Hagiwara et al Discussion CD109 is a GPI-anchored cell surface glycoprotein with a furinase cleavage motif. In this study, we characterized the nature and biological roles of the CD109 protein using antibodies that recognize different CD109 epitopes. We first investigated whether CD109 is cleaved by furinase. Furin is a calcium-dependent serine endoprotease that functions in the trans-Golgi network and cleaves precursor proteins into their active forms (Nakayama, 1997; Thomas, 2002) . Target proteins include proparathyroid hormone, membrane type-1 matrix metalloproteinase, von Willebrand factor and TGF-b1 precursor (Gentry and Nash, 1990; Dubois et al., 1995) . We found that CD109 is translated as a 155 kDa core polypeptide and is processed into the 205 kDa mature glycoprotein in the Golgi via the 190 kDa immature glycoprotein (probably high mannose form). The 205 kDa CD109 was further processed by furinase into 180 kDa and 25 kDa CD109, both of which were subsequently localized on the cell surface. Treatment of CD109 transfectants with furinase inhibitor or introduction of a single amino acid substitution in the furinase cleavage motif (R1273S mutant) inhibited this processing, confirming the cleavage of CD109 by furin.
We also found that 25 kDa CD109 was a GPIanchored protein that was highly enriched on lipid rafts. Cleaved 180 kDa CD109 was not only associated with 25 kDa CD109 but was also secreted into the culture medium. Immunoprecipitation experiments revealed the association of 25 kDa and 180 kDa CD109 complex with TbRI. These results confirmed the report by Finnson et al. (2006) , which showed that CD109 interacted directly with TbRI, independently of ligand binding. Interestingly, the furinase-resistant CD109 R1273S was not able to associate with TbRI, although the R1273S mutant protein was localized on the cell surface. These findings indicate that processing from the 205 kDa form to the 180 kDa and 25 kDa forms by furinase cleavage is a prerequisite for the association of CD109 with TbRI on the cell surface. Further investigation is necessary to further understand the complexes that these proteins form.
CD109 R1273S lost the ability to negatively regulate TGF-b1 signaling. The levels of Smad2 phosphorylation and the expression of its downstream target, p21, were significantly decreased in wild-type CD109-expressing Role of furin-processed CD109 in TGF-b signaling S Hagiwara et al cells, but not in CD109 R1273S-expressing cells. In addition, overexpression of CD109, but not R1273S, accelerated cell proliferation and this acceleration was not affected by TGF-b1 treatment. These results also showed that cleavage of CD109 by furinase is important for its biological functions. As overexpression of the 25 kDa form alone did not affect TGF-b1 signaling, the complex of cleaved 25 kDa and 180 kDa CD109 on the cell surface appears to regulate the function of TbRI. We have reported that CD109 is expressed at higher levels in human SCCs of various tissues compared with other tumors of different histology. In addition, we found that in oral cancer the levels of CD109 expression were significantly higher in well-differentiated SCCs and high-risk premalignant lesions than in poorly differentiated SCCs. Furthermore, it has been reported that the levels of TbRI and TbRII expression were significantly higher in well-differentiated SCCs than in poorly differentiated SCCs (Wang et al., 2009) . TGF-b1 is known to have dual tumor-suppressive and promoting effects, depending on the tumor stage (Wakefield and Roberts, 2002; Bierie and Moses, 2006; Leivonen and Ka¨ha¨ri, 2007) . TGF-b1 shows anti-proliferative effects on normal epithelial cells and during the early tumor stage. This effect then decreases and the tumor promoting effect becomes prominent as the tumor stage advances. Our findings may suggest a role of CD109 as a negative modulator of TGF-b signaling during early stages of carcinogenesis.
We show that 180 kDa CD109 is efficiently secreted into the culture medium. As CD109 binds TGF-b1 with high affinity, secreted 180 kDa CD109 may also contribute to negative regulation of TGF-b1 signaling by sequestration of TGF-b1 in the medium. However, inhibition of TGF-b signaling by CD109 can occur independently of ligand sequestration via direct modulation of TbRI activity (Finnson et al., 2006) . In this study, we showed that overexpression of 180 kDa soluble CD109 also inhibits TGF-b signaling, suggesting that soluble CD109 can bind to TbRI. In addition, it is worth investigating whether soluble CD109 is detected in sera from cancer patients with SCC. Establishing an assay to measure the amount of CD109 in sera may facilitate the early diagnosis of SCC or its recurrence.
Materials and methods
Cell lines HEK293 (derived from human embryonic kidney), A431 and SK-MES-1 (derived from human skin and lung squamous cell carcinoma, respectively) cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 8% fetal bovine serum (FBS) at 37 1C in 5% CO 2. HEK293 cells expressing exogenous human CD109 were grown in 8% FBS-DMEM containing 400 mg/ml Geneticin (Invitrogen, Carlsbad, CA, USA).
Vector construction FLAG-tagged full-length human CD109 cDNA (FLAG-CD109) was cloned into pcDNA3.1( þ ), as described previously . cDNA fragments were amplified by PCR using Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). The FLAG sequence, consisting of eight amino acids (aa.), was inserted just after the N-terminal signal sequence of CD109. Arginine 1273, in the furinase cleavage motif, was replaced with serine (R1273S; nucleotide 3931, A to C) by sitedirected mutagenesis of FLAG-CD109. A FLAG-tagged truncated CD109 cDNA fragment (aa. 1 to 1273; designated sCD109) was also cloned into pcDNA3.1( þ ). A Myc-tagged C-terminal CD109 fragment (aa. 1274-1445; designated MyccCD109) was inserted between EcoRV and XhoI sites of pSecTag2B (Invitrogen), and transformed to E. coli (DH5a).
Generation of transfectants HEK293 cells were transfected with FLAG-CD109, FLAG-CD109 R1273S or pcDNA3.1( þ ) empty vector using Lipofectamine 2000 (Invitrogen). Forty eight hours after transfection, the cells were incubated for 1 week in selection medium containing 400 mg/ml of Geneticin. Geneticin-resistant colonies were picked and cultured in selection medium for another week. The expression level of CD109 in each clone was assayed by western blot analysis with anti-FLAG monoclonal antibody. Myc-cCD109 was also transfected into HEK293 cells using Lipofectamine 2000, and cells transiently expressing CD109 were prepared for several experiments.
Antibodies and reagents
Three anti-CD109 antibodies were generated by immunization with synthetic peptides of human CD109 (aa. 461-478 for Western blot analysis Cells were lysed with sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl; pH 6.8, 2% SDS, 25% Glycerol, 20 mg/ml bromophenol blue), containing 1 mM phenylmethylsulfonyl fluoride and 4 mM Na 3 VO 4 , and sonicated until no longer viscous. After measuring the concentration of the protein using a BCA kit (Bio-Rad, Hercules, CA, USA), the lysates were boiled at 100 1C for 2 min in the presence of 2% b-mercaptoethanol. Equal amounts of protein were separated by SDS-5B12% polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Membranes were blocked for 60 min with 5% albumin in TBST buffer (20 mM Tris-HCl; pH 7.6, 137 mM NaCl, 0.1% Tween 20), and incubated with primary antibodies for 60 min at room temperature (RT). After washing the membranes three times with TBST, they were incubated with secondary antibodies for 60 min at RT. After washing the membranes, the reaction was visualized using the ECL Detection Kit (GE Healthcare, Buckinghamshire, UK).
Immunoprecipitation
Cells were lysed at 4 1C for 60 min in 500 ml of Triton X-100 buffer (1% Triton X-100, 25 mM Tris-HCl; pH 8.0, 150 mM NaCl, 10 mM EDTA, 1 mM PMSF, Complete Mini 1 Tab/ 10 ml) and clarified by centrifugation. The soluble fraction was pre-incubated with 10 ml of Protein A or G-Sepharose beads (Sigma) for 30 min at 4 1C. After removing the beads by centrifugation, the samples were incubated overnight at 4 1C with 0.5 mg of each precipitation antibody. The immune complexes were isolated by adding 30 ml of Protein A or G-Sepharose for 2 h at 4 1C, and these beads were washed four times with Triton X-100 buffer. The bead-bound immune complexes were resuspended in 100 ml of SDS sample buffer containing 5% b-mercaptoethanol, and heated at 100 1C for 2 min. After removing the beads by centrifugation, the samples were analyzed by SDS-PAGE.
RNA interference
SiRNA-mediated knockdown of CD109 was performed using an siGENOME SMART pool specific to human CD109 purchased from Dharmacon (Lafayette, CO, USA). Cells were transfected with siRNA (50 nM) using Lipofectamine RNAi-MAX reagent (Invitrogen) according to the manufacturer's protocols. After incubation for 48 h, siRNA-treated cells were used for several assays.
Cell surface biotinylation Subconfluent monolayer cells were washed three times with biotinylation buffer (10 mM HEPES; pH 8.8, 150 mM NaCl). Biotin (Long arm) NHS-Water Soluble (Vector Laboratories, Burlingame, CA, USA) was dissolved in biotinylation buffer and added to cells at a final concentration of 50 mg/ml. After incubation for 10 min at 20 1C, the reaction was terminated by the addition of NH 4 Cl at a final concentration of 10 mM. Cells were washed with 50 mM Tris-HCl (pH 7.4) containing 25 mM KCl, 5 mM MgCl 2 and 1 mM EDTA, and lysed in Triton X-100 buffer. The lysates were used for immunoprecipitation.
CD109 processing analysis CD109 biosynthesis and processing were analyzed using several inhibitors. A 10 mM stock solution of FI-I was prepared in DMSO and diluted into culture medium to give the required final concentration. Furin (Furinase) is a major processing enzyme, mainly localized in the trans-Golgi network, and whose minimal specific sequence is Arg-X-(Lys/Arg)-Arg (Ouweland et al., 1990; Molloy et al., 1992; Rouille´et al., 1995; Steiner, 1998) . Tunicamycin, a streptomycete antibiotic (Takatsuki et al., 1971) , specifically inhibits the glycosylation of proteins at asparagine residues (Struck and Lennarz, 1977; Waechter and Harford, 1977; Guarnaccia et al., 1983; Arnold et al., 2006) . A 1 mg/ml tunicamycin stock solution in 10 mM NaOH was prepared, and added to culture media at a final concentration of 5 mg/ml.
Cell proliferation assay
Cells were seeded in 96-well plates (1 Â 10 3 cells per well) in 100 ml of DMEM supplemented with 4% FBS and incubated for 24 h. After removing the medium, 100 ml of fresh medium, with or without TGF-b1, was added. The cell proliferation assay using WST-1 reagent (Roche, Basel, Switzerland) was performed according to the manufacturer's protocol. Absorbance was measured at 450-620 nm every 24 h using a microplate reader (Tecan, Palm Springs, CA, USA).
Fluorescence microscopy Cells were fixed in 100% methanol for 20 min at À20 1C, followed by permeabilization with phosphate-buffered saline containing 0.5% Triton X-100 for 3 min. Slides were blocked in phosphate-buffered saline containing 1% BSA for 30 min at 37 1C. Samples were stained with primary antibodies for 1 h, followed by incubation with AlexaFluor 488 or 594-conjugated secondary antibody for 30 min at 37 1C. Nuclear staining was performed with DAPI or PI after incubation with secondary antibodies. The slides were mounted with PermaFluor Mounting Medium (Thermo, Pittsburgh, PA, USA). Microscopic observation was performed using an Olympus IX71/Fluoview-FV500 confocal laser scanning system at Â 60 magnification.
Statistical analysis
Statistical significance of the measured values was analyzed using the two-tailed Student's t-test. Po0.05 was considered significant.
